Aurobindo Pharma gets FDA approval for generic equivalent of Xarelto

The anticoagulant drug, which has an estimated US market size of $447 million, is set to be launched in the first quarter of the 2025-26 fiscal.

13 April, 20252 min
0
Banner image

Subscribe to read this story

We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.

$99 for one year

SUBSCRIBE
Already have an account? Sign In

Not ready to subscribe? Sign up for a free account

We value our free readers. Read 100+ stories every year.

You may also like

Business
Story image

Has Aurobindo Pharma left its wild swings behind?

The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.

Business
Story image

Is Aurobindo Pharma the most underrated pharma company?

The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.